LY1

• Description :

  LY1 is a potent, selective and covalent inhibitor against both SARS-CoV-2 PLpro and Mpro with Kd values of 1.5 μM and 2.3 μM for Mpro C145A protein and PLpro C111A protein, respectively. LY1 potent against the viral proteases, with IC50s of 0.12 μM and 0.99 μM against Mpro and PLpro. LY1 shows high selectivity over other kinases, human proteases and metalloenzyme[1].

• UNSPSC :

  12352005

• Target :

  SARS-CoV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/ly1.html

• Purity :

  98.01

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C1C=C(C2=NS(=O)(C3=C2C1=CC=C3)=O)NC4=C(C=CC=C4)N5CCNCC5.Cl

• Molecular Formula :

  C20H19ClN4O3S

• Molecular Weight :

  430.91

• References & Citations :

  [1]Wenying Yu, et al. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2. J Med Chem. 2022 Dec 22;65 (24) :16252-16267.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2883813-32-7]